ReviewFrontiers in endocrinology2025
Pharmacological and non-pharmacological modulation of endoplasmic reticulum stress in pediatric diabetes.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Analysis ofInternational journal of molecular sciences · 2026Article
- Stress-driven remodeling of antigen presentation and chemokine signaling in pancreatic β-cells: implications for type 1 diabetes.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In all forms of pediatric diabetes, the endoplasmic reticulum (ER) stress acquires a significant role, as a factor that contributes to the dysfunction and apoptosis of the pancreatic β- cells. The integrity of the ER response is critical as a molecular mechanism for alleviating stress during insulin biosynthesis and processing, regardless of the diabetes subtype. While achieving euglycemia remains central to diabetes management, there is growing recognition that targeting ER stress presents a promising therapeutic strategy, given that accumulating evidence shows that ER stress acts not only as a consequence but also as a key contributor to diabetes pathogenesis. This review explores the mechanisms of ER stress across all forms of diabetes, discusses both pharmacological and non-pharmacological approaches to modulating ER stress-with particular attention to medications that are already approved for use in children, such as metformin -and examines the potential of combining ER stress modulation with insulin therapy in order to optimize the metabolic homeostasis for the β-cell function and survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.